Purpose: Inhibition of COX-2 enzymes is a frequently suggested mechanism for the beneficial effects of NSAIDs on carcinogenesis. The aim of this study was to explore the role of cumulative NSAID use on four common non-skin related cancers and modification by COX-2 G-765C genotype. Patients and methods: 7621 participants of The Rotterdam Study were included. In a mean follow up period of 10 years, 720 colorectal, lung, breast or prostate cancers occurred. Cumulative NSAID use was calculated per NSAID class. Individual associations of NSAID use and COX-2 G-765C genotype on cancer risk were explored with Cox' proportional hazard models. Next, the association of NSAIDs and cancer stratified by COX-2 genotype was studied. Finally, the effect of combinations of NSAID use and COX-2 genotype on survival times was investigated. Results: All NSAID classes were associated with a reduced risk of colorectal cancer but not of other cancers. No associations between COX-2 genotype and incident cancer, overall or cancer specific mortality were observed. COX-selective NSAIDs showed modest further risk reduction. Survival times were more than twice as long for carriers of a COX-2 C-765 allele with colorectal cancer who used NSAIDs in the five years prior to diagnosis than for patients homozygous for the wild type (G-765) without NSAID use (p = 0.007). Conclusion: Our results confirm the protective effect of NSAID use on colorectal cancer. Individuals diagnosed with colorectal cancer who carry a COX-2 C-765 allele and are on NSAIDs have an increased survival in comparison to non-users with the wild type (G -765).

Additional Metadata
Keywords Anti-inflammatory agents, Cohort study [MeSH], Cyclooxygenase 2 (inhibitors) [MeSH], Neoplasms [MeSH], Non-steroidal [MeSH], Polymorphism, Single nucleotide [MeSH]
Persistent URL dx.doi.org/10.2174/156800908786733414, hdl.handle.net/1765/74854
Journal Current Cancer Drug Targets
Siemes, C, Visser, L.E, Coebergh, J.W.W, Hofman, A, Uitterlinden, A.G, & Stricker, B.H.Ch. (2008). Protective effect of NSAIDs on cancer and influence of COX-2 C-765G genotype. Current Cancer Drug Targets, 8(8), 753–764. doi:10.2174/156800908786733414